Here you can find more information about the projects we are funding that are developing the treatment pipeline. Click on a project to find out more information and what the project means to a person living with MND.
These projects aim to turn the most promising scientific discoveries into potential new treatments. New treatments that have been proven safe and effective by all other methods are then carefully tested in people.
Gene activity in MND: from disease mechanisms to treatment opportunity
Dr Carlo Rinaldi
Development of RAR class ligands for treatment of MND
Prof Peter McCaffery
MND Association and LifeArc Joint Collaborative Partnership- United2EndMND - Phase 1
Prof Ammar Al-Chalabi and Prof Chris McDermott
Developing a novel cell therapy approach to restore lost muscle function in MND
Dr Barney Bryson
Developing and testing a new gene therapy approach for TDP-43 associated MND
Prof Pietro Fratta
Investigating membrane lipid rafts as a therapeutic target in ALS
Dr Tobias Moll
Developing a new gene therapy as a tool to rescue TDP-43 related gene changes in MND
Dr Puja Mehta
The role of TBK1-dependant immune signalling pathways in MND
Dr Valeria Gerbino
Analysis of candidate compounds for drug repurposing in MND
Prof Kevin Talbot
Assessing the dosing and effectiveness of compounds targeting TDP-43 aggregation in MND
Dr Mark Baker
Development of new compounds to help target faulty SOD1 protein as a potential treatment of MND
Prof Samar Hasnain
Improving the safety and specificity of a new gene therapy system for MND
Dr Oscar Wilkins